Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R25TW009337 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fogarty International Center of the National Institute of Health | NIH |
| Moi University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sepsis is a clinical syndrome representing deranged hemodynamics (such as tachycardia) secondary to severe infection. In high-income countries (HICs), early resuscitation of septic patients with protocol-driven therapy, including quantitative fluid administration guided by invasive monitoring, has resulted in improved outcomes for septic patients. Prevalence and mortality of sepsis are thought to be higher in sub-Saharan Africa (SSA) than in high-income countries; however, most hospitals in SSA lack the technology and resources necessary to implement the resuscitation protocols used in HICs and therefore, mortality from sepsis remains high. The World Health Organization (WHO) has recently disseminated an algorithm for resuscitation of septic patients in low resource settings. This algorithm is based on expert consensus only, and its efficacy has never been tested.
This study will be conducted in the Casualty Department of Moi Teaching and Referral Hospital (MTRH) in Eldoret, Kenya.
The purpose of this study is to describe the epidemiology of patients presenting with severe sepsis, to examine the microbiology causing severe sepsis, to describe current management and outcomes for severe sepsis, and to test the effect of implementation of the WHO resuscitation algorithm at MTRH.
The study design is a prospective before and after clinical trial. In an initial observational phase, adult patients presenting to the MTRH Casualty Department with sepsis and severe sepsis (the latter of which will be defined by elevated lactate) will be enrolled into a prospective observational cohort. Demographic data, medical characteristics, and microbiological studies will be obtained, then the management and outcomes of these patients will be observed. In a second phase, patients with sepsis will continue to be enrolled into a prospective observational cohort, while patients with severe sepsis will be enrolled into an intervention group. Patients in the intervention group will be managed according to the WHO resuscitation algorithm. Specifically, the WHO algorithm involves fluid boluses guided by vital signs and physical exam findings, rapid and early administration of empiric antibiotics, and frequent patient monitoring. The outcomes of interest are achievement of lactate clearance, which is a correlate of tissue perfusion, as well as 24-hour, in-hospital, and 30-day mortality.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| WHO intervention | Experimental | This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia. |
|
| Standard care | No Intervention | This arm will be managed per standard care by the hospital clinicians. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WHO algorithm of fluid boluses guided by physical examination | Other |
| ||
| Frequent patient monitoring |
| Measure | Description | Time Frame |
|---|---|---|
| Lactate clearance (difference in lactate [mmol/L] at study enrollment and 6 hours after study enrollment) as a measure of efficacy | Lactate level will be measured at study enrollment (time 0) and 6 hours after study enrollment (time 6). Lactate clearance will be reported as the difference between time 0 and time 6 lactate, as a fraction of time 0 lactate. | enrollment, 6 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | 24 hours, in-hospital, and 30 days | |
| Number of subjects with adverse effects as a measure of safety | 6 hours, 24 hours, in-hospital, and 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Time of first antibiotic delivery | 1 hour | |
| IV fluid volume (ml) | 6 hours, 24 hours, in-hospital |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nathan M Thielman, MD, MPH | Duke University | Principal Investigator |
| Charles Kwobah, MBChB, MMed | Moi University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Moi Teaching and Referral Hospital | Eldoret | Kenya |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
Vital signs and physical exam every 30-60 minutes |
|
| Early administration of empiric antibiotics | Other | Clinician will be prompted to administer antibiotics within 60 minutes |
|
| Oxygen delivery | Other |
|
| Correction of hypoglycemia | Other | If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered |
|
| Correction of severe anemia | Other | If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion |
|
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
Not provided
Not provided